

References

I-201

1. Onpattro (patisiran). [prescribing information] Alnylam Pharmaceuticals, Inc., Cambridge, MA. 08/2018.
2. Yukio A, Coelho T, Berk J, et al. Guideline of Transthyretin-Related Hereditary Amyloidosis for Clinicians. *Orphanet J Rare Dis*. 2013;8(31):1-18.
3. Adams D, Gonzalez-Duarte A, O’Riordan W, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. *N Engl J Med*. 2018;379:11-21.
4. Adams D, Suhr O, Dyck P, et al. Trial Design and Rationale for APOLLO, a Phase 3, Placebo-Controlled Study of Patisiran in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy. *BMC Neuro*. 2017;17:1-12.
5. Gonzalez-Duarte A, Lem-Carrillo M, & Cardenas-Soto K. Description of Transthyretin S50A, S52P and G47A Mutations in Familial Amyloidosis Polyneuropathy. *Amyloid*. 2013;20(4):221-225.
6. Benson M, Waddington-Cruz M, Berk J, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. *N Engl J Med*. 2018;379(1);22-31.
7. Tegsedi (inotersen). [prescribing information] Akcea Therapeutics, Inc., Boston, MA. 10/2018.
8. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
9. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.
10. ASHP Guidelines on Home Infusion Pharmacy Services, 2013.